...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith funding???
5
Jun 15, 2019 01:28PM
4
Jun 15, 2019 07:08PM
4
Jun 15, 2019 09:33PM
4
Jun 16, 2019 07:41AM
3
Jun 16, 2019 12:37PM
3
Jun 17, 2019 01:57PM
3
Jun 17, 2019 04:53PM
2
Jun 17, 2019 05:00PM
2
Jun 18, 2019 12:19PM
2
Jun 24, 2019 01:48PM
3
Jun 24, 2019 04:43PM
6
Jun 25, 2019 12:44AM
4
Jun 25, 2019 10:59AM
7
Jun 25, 2019 11:45AM
4
Jun 25, 2019 12:45PM

KOO - I'm not sure if you are asking me a question and if so, exactly what. You might be totally correct on what you stated but that is money that Zenith has to give to RVX putting them into debt. It also has to show in their financial statements. It shows as US$2.010 million of net R&D and US$573,000 as General & Administrative for US$2.583 million divided by three for US$860,000/month over the quarter ending Jan. 31st. Is that what you were questioning?

From Jan. 31st to June 30th is 5 months at US$860,000/month or the 9 month average burn of US$800,000 which gives US$4mm - US$4.3 million of burn only covered by $83,000 cash at Jan. 31st.

4
Jun 25, 2019 01:17PM
3
Jun 25, 2019 01:37PM
5
Jun 25, 2019 02:54PM
4
Jun 25, 2019 03:01PM
3
Jun 26, 2019 12:16PM

Jun 26, 2019 01:02PM
3
Jun 26, 2019 02:30PM
Share
New Message
Please login to post a reply